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Abstract
Approximately 30% of Americans suffer from chronic pain disorders, such as fibromyalgia (FM), 
which can cause debilitating pain. Many pain-killing drugs prescribed for chronic pain disorders 
are highly addictive, have limited clinical efficacy, and do not treat the cognitive symptoms 
reported by many patients. The neurobiological substrates of chronic pain are largely unknown, 
but evidence points to altered dopaminergic transmission in aberrant pain perception. We sought to 
characterize the dopamine (DA) system in individuals with FM. Positron emission tomography 
(PET) with [18F]fallypride (FAL) was used to assess changes in DA during a working memory 
challenge relative to a baseline task, and to test for associations between baseline D2/D3 
availability and experimental pain measures. Twelve female subjects with FM and eleven female 
controls completed study procedures. Subjects received one FAL PET scan while performing a “2-
back” task, and one while performing a “0-back” (attentional control, “baseline”) task. FM 
subjects had lower baseline FAL binding potential (BP) in several cortical regions relative to 
controls, including anterior cingulate cortex. In FM subjects, self-reported spontaneous pain 
negatively correlated with FAL BP in the left orbitofrontal cortex and parahippocampal gyrus. 
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Baseline BP was significantly negatively correlated with experimental pain sensitivity and 
tolerance in both FM and CON subjects, although spatial patterns of these associations differed 
between groups. The data suggest that abnormal DA function may be associated with differential 
processing of pain perception in FM. Further studies are needed to explore the functional 
significance of DA in nociception and cognitive processing in chronic pain.
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INTRODUCTION
Nociception is a normal process that is crucial for an organism’s survival. However, in 
conditions such as fibromyalgia (FM), there is likely a dysfunction in perceptual processing 
which results in constant (or chronic) pain. An estimated 30.7% of Americans suffer from 
various chronic pain disorders (Johannes et al. 2010), which can negatively affect multiple 
facets of everyday life, often to the point of debilitation. Depression, anxiety, and cognitive 
complaints are highly comorbid with chronic pain disorders (Asmundson and Katz 2009; 
Berryman et al. 2013; Gureje 2007). Unfortunately, many of the pain-killing medications 
prescribed to individuals with chronic pain are highly addictive, have limited clinical 
efficacy, and do not treat the cognitive symptoms reported by patients (Ballantyne and Shin 
2008; Kuijpers et al. 2011). Therefore, there is a critical need to elucidate the neural 
substrates of pain perception in order to inform development of more effective therapeutic 
strategies.
Recent evidence from human imaging studies in healthy controls implicates a regulatory role 
for dopamine (DA) in nociception during experimentally evoked pain (Hagelberg et al. 
2002; Wood et al. 2007; Martikainen et al. 2005; Pertovaara et al. 2004; Scott et al. 2006). 
Given this evidence, it is possible that aberrant DA signaling may be linked to the perception 
of moderate to severe chronic pain. Indeed, alterations of DA function have been 
documented in several chronic pain disorders, including FM (Wood et al. 2009; Wood et al. 
2007), restless legs syndrome (Cervenka et al. 2006), burning mouth syndrome (Hagelberg 
et al. 2003b), and atypical facial pain (Hagelberg et al. 2003a). Whereas these studies 
focused on striatal DA function, very little is known about the role of cortical DA function in 
chronic pain.
In addition to a putative role in nociception, DA is essential for cognitive function (for a 
comprehensive review, see Nieoullon 2002). Therefore, it is possible that DA may mediate 
the cognitive complaints often reported by chronic pain patients (McCracken and Iverson 
2001; Williams et al. 2011). Consistent with this hypothesis, recent BOLD fMRI data 
suggest that individuals with FM have a significantly lower level of working memory-
induced brain activation compared to controls (Seo et al. 2012), which is supportive of the 
concept that cortical cognitive processing may be altered in FM. However, the 
neurochemical basis for these observations is unclear.
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In order to help elucidate the dopaminergic (DAergic) contributions to the pain experience 
and potential cognitive compromise in chronic pain disorders, we conducted a pilot study in 
individuals with FM using positron emission tomography (PET) and [18F]fallypride (FAL). 
The primary objective of the current study was to ascertain how striatal and extrastriatal DA 
signaling might differ in individuals with chronic pain. Although many pain disorders may 
share common neurological substrates, the literature suggests that neurochemical differences 
exist among various pain populations (Apkarian et al. 2009). Thus, in order to reduce 
variance within our sample, we chose to study individuals that fit diagnostic criteria for FM 
syndrome.
We hypothesized that: (1) FM and CON groups would have different central DA tone 
(reflected by differences in baseline DA D2/D3 receptor binding); (2) relative to controls, 
FM subjects would exhibit different patterns of DA release in response to a working memory 
(WM) task; and (3) baseline DA D2/D3 availability would be associated with spontaneous 
self-reported pain levels in FM subjects, and with experimental pain measures in both FM 
and CON subjects.
METHODS
All study procedures were approved by the Indiana University Institutional Review Board 
and performed in accordance with the ethical standards of the Belmont Report. Written 
informed consent was obtained from all patients prior to participation in the study. Subjects 
were recruited by local advertising in the greater Indianapolis area. Twelve female subjects 
with fibromyalgia (FM) and twelve control female subjects (CON) completed all study 
procedures. Subjects underwent a screening interview that included the Structured Clinical 
Interview for DSM-IV disorders (SCID) I and II, the Beck Depression Inventory (BDI; Beck 
et al. 1961), the State-Trait Anxiety Scale (STAI; Spielberger 1983), the Positive and 
Negative Affect Scale (PANAS; Watson et al. 1988), the Edinburgh Handedness Inventory 
(Oldfield 1971), the Fagerström Test for Nicotine Dependence (Pomerleau et al. 1994), and 
the Time Line Follow Back calendar for recent drinking (TLFB; Sobell et al. 1986). Two FM 
subjects endorsed current major depressive episode and were taking prescription 
antidepressants. The control group included two subjects matched for diagnosis of current 
major depressive episode and medication status. Exclusion criteria were: age less than 18 or 
greater than 45, history of Axis I disorders (excluding mood and anxiety disorders), history 
of seizures, intake of >14 alcoholic drinks per week, current use of illicit drugs (sporadic 
marijuana use excepted), current use of medications with known dopaminergic interactions 
(including selective norepinephrine reuptake inhibitors and daily use of prescription opiates), 
contraindication for MRI, and a positive urine toxicology screen (Q-10, Proxam) on 
screening and/or PET imaging days. Two FM subjects reported sporadic, as-needed use of 
prescription opiate painkillers, and another reported as-needed use of benzodiazepines. 
However, no subjects tested positive for either drug class on either scan day. FM-specific 
exclusion criteria were: failure to meet diagnostic criteria for FM (Wolfe et al. 1990) as 
determined by a pain specialist (co-author P.M.), and presentation of any comorbid pain 
disorder(s). Subjects received two [18F]fallypride (FAL) PET scans, conducted on separate 
days. Scan order was counterbalanced across subjects. The baseline FAL scan was acquired 
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while subjects performed a control attention task (BL; 0-back task). The challenge FAL scan 
was acquired while subjects performed a working memory task (WM; 2-back task).
Subjective Pain Ratings
Questionnaires—Multiple self-reported pain assessments were conducted. At the 
beginning of each scan day, subjects completed the short-form McGill Pain Questionnaire 
(MPQ; Melzack 1987), Fibromyalgia Impact Questionnaire (FIQ; Burckhardt et al. 1991), 
and the Brief Pain inventory (BPI; Cleeland and Ryan 1994). Additionally, to characterize 
self-reported pain intensity during scanning, subjects periodically rated their current pain on 
a computerized visual analog scale (VAS), anchored by 0 (no pain at all) and 100 (worst 
pain possible). Subjects were prompted to respond to the VAS query every ten minutes 
throughout scanning, for a total of 15 responses. For each subject and each scan, the average 
VAS score over the entire scan session was calculated.
Pressure Sensitivity Testing—Six of the 18 FM “tender points” were selected for 
determination of each subject’s mechanical pain sensitivity and tolerance: bilateral second 
rib, bilateral trapezius muscle, and the bilateral medial fat pads of the knee (Wolfe et al. 
1990). A JTech Commander Algometer (JTech Medical, Salt Lake City, UT) with a rubber 
disc of 1cm2 was applied at 90° to each of these points. Pressure was initially applied at an 
approximate rate of 3 Newtons/cm2/s to determine subjects’ sensitivity (that is, the level of 
pressure at which the subject initially perceives the sensation of pain). To assess pain 
tolerance, pressure was gradually increased until the pain was almost unbearable. Pressure 
was withdrawn immediately after subjects indicated their tolerance point. Both sensitivity 
and tolerance were recorded in N/cm2. Mechanical sensitivity and tolerance were assessed 
the morning of each scan day. Measurements of sensitivity and tolerance, respectively, were 
averaged across all six tender points for each day.
Cognitive Testing
N-back Task—“0-back” (BL) and “2-back” (WM) tasks were modified versions used by 
McDonald et al. (2012), and programmed in E-prime 2.0 software (Psychology Software 
Tools Inc., Sharpsburg, PA).
For each run of the “0-back” task, subjects were given a target letter prior to initiation of the 
task, and instructed to respond each time a stimulus letter matched the target letter.
For each run of the “2-back” task, subjects were instructed to respond when a stimulus letter 
matched a stimulus presented two back in the letter sequence.
During both tasks, subjects were presented with stimulus letters (all consonants, excluding 
L, W, and Y) for 2s with a blank screen inter-stimulus interval of 1.5s. Each task run 
consisted of 90 stimulus presentations, with 23 potential correct responses. Tasks were 
presented to subjects on a computer monitor situated outside the gantry, in full view of the 
subject. Initiation of tasks began five minutes prior to FAL injection. Individual task runs 
were presented four times, with a ~5 minute break between runs. Prior to tracer injection, 
study personnel ensured that the subject was able to easily see, read, and perform the task 
without significant head movement. Short practice sessions were conducted prior to 
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scanning to ensure the subject understood task requirements. Task responses were made via 
a wireless mouse located on a table next to the scanner bed. Responses were given by 
clicking the left mouse button.
The number of correct responses, false positive responses, omitted responses, and respective 
reaction times were automatically recorded. Percent correct (adjusted for guessing) and 
average reaction time were calculated as outcome variables.
Additional Cognitive Tests—Three additional cognitive tests were administered prior to 
scanning on the baseline (“0-back”) scan day. The Paced Auditory Serial Addition Task 
(Gronwall 1977), and age-scaled scores from the Arithmetic and Digit Span subtests of the 
WAIS-III (Wechsler 1997) were administered to assess attention and working memory 
performance.
Image Acquisition
A magnetized prepared rapid gradient echo (MP-RAGE) magnetic resonance image (MRI) 
was acquired using a Siemens 3T Trio-Tim for anatomic coregistration and processing of 
PET data. Acquisition of [18F]fallypride (FAL) data was similar to that described previously 
(Albrecht et al. 2014). Briefly, FAL was synthesized in the Department of Radiology and 
Imaging Sciences radiochemistry facilities (Gao et al. 2010). FAL PET scans were acquired 
on a Siemens ECAT HR+ (3D mode; septa retracted). FAL PET scans were initiated with an 
IV FAL infusion into the antecubital vein over the course of 1.5 minutes. The dynamic PET 
acquisition was split into two segments for subject comfort (Christian et al. 2006). The first 
half of dynamic acquisition was 70 min (6 × 30s, 7 × 60s, 10 × 120s, 10 × 300s). Following 
this segment, the subject was removed from the scanner for a ~20 min break period to 
stretch and use the restroom if needed. The second half of dynamic acquisition lasted 80 min 
(16 × 300s). A schematic of the scan day timeline is shown in Online Resource 1.
Image Processing
Processing of FAL data has been described previously (Albrecht et al. 2014). Dynamic FAL 
PET data were reconstructed with Siemens ECAT software, v7.2.2. Three-dimensional data 
were rebinned into 2D sinograms with Fourier rebinning. Data were corrected for 
attenuation, randoms, and scatter. PET images were generated via filtered back-projection of 
sinograms, using a 5mm Hanning filter. MRI and dynamic PET images were converted to 
Neuroimaging Informatics Technology Initiative (NIfTI) format (http://nifti.nimh.nih.gov/) 
and processed with SPM8. A mean PET image that contained a mixture of blood flow and 
specific binding (i.e. showed good gray to white matter contrast in both cortical and sub-
cortical regions) was created using the realignment algorithm. This mean PET image was 
coregistered to the subject’s anatomic MRI using the mutual information algorithm in 
SPM8. Motion correction was implemented with frame-by-frame coregistration, using the 
MRI-coregistered mean PET as the target image. Each subject’s MRI was spatially 
normalized to Montreal Neurological Institute (MNI) space and the transformation matrix 
obtained from the spatial normalization step was then applied to the motion-corrected PET 
data from each subject.
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Voxel-wise Analysis
Dopamine (DA) D2/D3 receptor binding was indexed with binding potential relative to 
nondisplaceable binding (BPND; for notational simplicity, we will use the term BP), which is 
operationally defined as fND*Bavail/KD (Innis et al. 2007). FAL BP can be influenced by 
both the amount of DA D2/D3 receptors available for binding (Bavail) and endogenous DA 
concentration (which affects both Bavail and KD, the dissociation constant for FAL). fND is a 
term that represents unbound radioligand in tissue (please see Innis et al., 2007, for explicit 
tracer kinetic modeling definitions). Cerebellar gray matter (vermis excluded) was used as 
the reference region (tissue that contains few to no D2/D3 receptors). Individual cerebellar 
regions of interest (ROIs) were created for each subject in order to extract cerebellar time 
activity curves. BP was estimated at each brain voxel with Logan reference graphical 
analysis (Logan et al. 1996) using the cerebellar time activity curve as the input function. t* 
was set at 25 data points in “stretched” time. The resulting parametric BP images were 
smoothed with an 8mm Gaussian kernel (Costes et al. 2005; Picard et al. 2006; Ziolko et al. 
2006). Voxels in the parametric BP images that had values < 0.1 were excluded from further 
analysis to ensure that only reliably estimated BP values from both scans were considered.
Statistical Analysis
To assess group differences in demographic, affective, pain, and cognitive variables, 
independent t-tests were conducted for continuous and ordinal data; frequency was assessed 
with chi-squared tests. Tracer parameters were analyzed with a one-way ANOVA with 
group, scan, and group*scan as factors. Analyses were conducted with SPSS 21, with a two-
tailed significance threshold of p < 0.05.
To analyze FAL BP data, parameteric images were entered into a 2-scan (BL, WM) × Group 
(CON, FM) full factorial model in SPM8. Model contrasts tested for baseline differences in 
FAL BP between groups, and for main effects of the working memory task. Voxel-wise 
regression models were used to test for relationships between baseline BP and pain metrics 
(in-scan VAS ratings, experimental pain tolerance, experimental pain sensitivity). In all 
analyses, an average gray matter map across all subjects was used to create an inclusive 
mask. Given the exploratory nature of the study, statistical threshold was set at p < 0.005, 
uncorrected, with cluster extent threshold k = 10. BLBP refers to BP during the baseline (“0-
back”) condition, and WMBP refers to BP during the working memory (“2-back”) condition. 
Any putative differences in BP between BL and WM scan conditions would be attributed to 
changes in endogenous DA concentration (i.e., decreases in task BP relative to baseline 
indicate increases in DA; conversely, increases in BP indicate decreases in DA). Significant 
clusters from the voxel-wise analyses were defined as regions of interest (ROI). To describe 
the effect sizes, average ROI BP values for the clusters were extracted from parametric 
images using the MarsBaR toolbox (http://marsbar.sourceforge.net/).
Baseline image data for one control subject were unusable. This subject was subsequently 
excluded from all analyses reported herein.
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RESULTS
Subject Characteristics
Subject demographics and affective characteristics are shown in Table 1. Groups were 
balanced for age, race, education, tobacco-smoking status, Axis I disorders, and medication 
status. FM subjects reported significantly higher depressive symptoms than CON subjects (p 
< 0.05). There were no group differences in the other affective scales.
FAL Tracer Characteristics
There were no effects of group, scan, or group*scan on either injected radioactivity (FM BL: 
193.4 ± 14.8 MBq; FM WM: 192.8 ± 13.7 MBq; CON BL: 188.6 ± 14.4 MBq; CON WM: 
187.6 ± 23.9 MBq) or injected mass (FM BL: 0.058 ± 0.04 nmol/kg; FM WM: 0.056 ± 0.04 
nmol/kg; CON BL: 0.053 ± 0.03 nmol/kg; CON WM: 0.064 ± 0.03 nmol/kg).
Pain Metrics
Pain metrics for FM and CON subjects are displayed in Table 2. Compared to CON, FM 
subjects reported significantly higher pain on every pain questionnaire, had higher VAS pain 
ratings during scanning, and had lower mechanical pain sensitivity and tolerance. Group 
differences were significant on both baseline and working memory scan days. Within-group 
paired-t tests revealed no significant effects of scan day (BL, WM) on any pain metric for 
either FM or CON groups (p > 0.05).
Cognitive Performance
Cognitive task results are presented in Online Resource 2. Relative to controls, FM subjects 
responded significantly more quickly during the 0-back task. However, there were no 
significant groups differences in %correct for either the 0-back or the 2-back task. FM 
subjects had significantly lower scores on the WAIS Digit Span subtest than controls (p < 
0.05). There was a trend for FM subjects to have lower scores on the Arithmetic subtest (p = 
0.06). All scores were within the normal range of cognitive function.
Group Differences in Baseline FAL BP
Voxel-wise analyses revealed several cortical regions in which FM FAL BLBP was 
significantly lower than CON FAL BLBP (Figure 1; Online Resource 3), including the 
anterior cingulate cortex (ACC) and fusiform gyrus. On average, FM BLBP was 29.6% lower 
than CON BLBP in these regions. There were no regions where FM BLBP was significantly 
higher than CON BLBP.
Effects of Working Memory Task on FAL BP
The working memory task did not induce any detectable changes in DA transmission as 
measured by FAL PET imaging. Across all subjects, there were no main effects of working 
memory task on FAL BPND (p > 0.005, uncorrected; k > 10).
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Baseline FAL BP is Negatively Associated with Current Subjective Pain in FM
Results from the voxel-wise multiple linear regression indicated that, in FM subjects, FAL 
BLBP was significantly negatively associated with average BL VAS pain ratings (Figure 2, 
Online Resource 4). FAL BLBP in the left orbitofrontal cortex and parahippocampal gyrus 
was significantly negatively correlated with VAS pain during BL scanning.
Baseline FAL BP is Negatively Associated with Experimental Pain – FM and CON
Sensitivity and tolerance to experimentally-induced pressure pain was significantly 
negatively correlated with FAL BLBP in several brain regions for both FM and CON 
subjects. In FM, the largest anatomic extent of the correlation between FAL BLBP and 
average sensitivity (onset of pain perception) was in bilateral parahippocampal gyrus, 
whereas in CON, the largest clusters were found in the cingulate gyrus and amygdala 
(Figure 3; see Online Resource 5 for a complete listing of regions with significant 
correlations). Pain tolerance in FM subjects was negatively related to FAL BLBP in 
hippocampus, ACC, bilateral striatum, and inferior frontal gyrus (IFG; Figure 4; see Online 
Resource 6 for a list of significant regions; see Online Resource 7 for a graphical 
representation in a selected region). Similarly, CON subjects also had negative correlations 
between tolerance and BLBP in the ACC and IFG, as well as in the thalamus and insula 
(Figure 4; Online Resources 6 and 7).
DISCUSSION
The principle finding from this pilot dataset is that extrastriatal dopamine (DA) transmission 
may be altered in fibromyalgia (FM). We found that FM subjects have lower cortical 
dopamine (DA) D2/D3 receptor binding availability relative to healthy controls. We also 
provide novel evidence that subjective rating of spontaneous pain in FM is negatively 
correlated with FAL BP in several brain regions. Finally, we show that sensitivity and 
tolerance to experimentally evoked pain is associated with baseline D2/D3 receptor 
availability. To our knowledge, this is the first demonstration that individuals with FM may 
have aberrant cortical DA function.
Our finding that FM subjects have lower baseline cortical DA receptor binding builds on 
existing evidence of differing striatal DA receptor binding in chronic pain populations 
(Cervenka et al. 2006; Hagelberg et al. 2003a; Hagelberg et al. 2003b; Wood et al. 2009; 
Wood et al. 2007). The present study revealed several cortical regions in which D2/D3 BP is 
lower in individuals with FM relative to healthy controls (Figure 1, Online Resource 3). 
Importantly, we detected effects in the ACC. This area is thought to be involved in the 
processing and regulation of emotional and affective components of pain (Lamm et al. 2011; 
Etkin et al. 2011). This has implications for chronic pain syndromes like FM, which have 
high comorbity of affective dysregulation. The presence of affective disorders in FM could 
influence both how individuals experience pain (Clauw 2009; van Middendorp et al. 2010) 
and how they self-report pain intensity (Johnson et al. 2010). Our data are consistent with 
the possibility that aberrant DA transmission within the ACC could potentially be associated 
with emotional disturbances and enhanced pain perception in FM. Somewhat less 
expectedly, we observed group differences in FAL BLBP in fusiform gyrus. Although the 
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fusiform gyrus is predominantly known for its role in face recognition (Kanwisher et al. 
1997), more recent evidence indicates involvement in emotional regulation (Fonville et al. 
2014; Harry et al. 2013). More germane to pain, empathy for pain (rather than being in pain 
oneself) has been shown to activate the fusiform gyrus in healthy controls (Gu et al. 2013; 
Singer et al. 2004). Taken together, the data suggest that the fusiform gyrus may be an area 
of interest of future research in FM and other chronic pain disorders.
The relatively lower cortical DA receptor binding in FM subjects reported here could also be 
relevant for cognitive processing in FM. Complaints of cognitive deficits are common in FM 
(Glass 2008), although not all reports have detected consistent differences in cognitive 
performance (Grace et al. 1999; Landro et al. 1997; Suhr 2003). Anterior cingulate regions 
are known to be involved with brain networks relevant for memory and perceptual function, 
including the default mode, executive, and cortical salience networks (Greicius et al. 2003; 
Seeley et al. 2007). Additionally, proper function of the ACC during cognition involves DA 
transmission (Aalto et al. 2005; Kodama et al. 2014). Taken together, it is perhaps not 
surprising that we detected differences in D2/D3 receptor binding in the ACC between FM 
subjects and controls. Subsequent work is necessary to further understand how cingulate DA 
transmission contributes to cognitive complaints in chronic pain syndromes.
We also observed that, in FM subjects, there were negative correlations between subjective 
spontaneous pain ratings during baseline scanning and FAL BLBP in OFC and 
parahippocampal gyrus (Figure 2; Online Resource 4). To the best of our knowledge, the 
current report represents the first evidence of a relationship between DA receptor availability 
and spontaneously-occurring pain in a chronic pain population. It may not be intuitively 
obvious that a relationship was observed between FAL BLBP and spontaneous pain in the 
OFC (known more for its role in stimulus valuation (Seymour and McClure 2008)) instead 
of established central pain nodes such as insula or S1. However, results from a recent fMRI 
study indicate that OFC activation during pain perception may encode relative pain valuation 
rather than pain intensity (Winston et al. 2014). Thus, it is possible that DAergic activity in 
FM is more related to assigning contextual value of pain rather than to the actual 
interoceptive signaling, raising the possibility that a dysregulation of pain valuation may 
underlie FM symptoms. Similarly, the parahippocampal gyrus is not typically included in 
discussions of traditional pain pathways (Apkarian et al. 2005). However, it is thought to be 
involved in the emotional regulation of pain and pain-related unpleasant stimuli (Fallon 
2013; Forkmann et al. 2013; Gosselin et al. 2006; Ploghaus et al. 2001; Stancak et al. 2013). 
Taken together, the data suggest that dopaminergic activity in the OFC and parahippocampal 
gyrus may be linked with the experience of spontaneous pain in individuals with FM.
Our final observations were correlations between experimentally administered pressure pain 
and FAL BLBP in both FM and CON groups (Figures 3 and 4, Online Resources 5, 6, and 7). 
In FM subjects, we observed a significantly negative association between pain tolerance and 
dorsal caudate FAL BLBP (Figure 4), which replicates previous findings in both healthy 
controls and chronic pain patients (Martikainen et al. 2005; Scott et al. 2006; Martikainen et 
al. 2015). However, we did not find a similar correlation in the caudate of our healthy 
control sample, which may be due to differences in group characteristics (see below). Of 
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note, Martikainen et al. (2015) also reported a significant negative correlation in chronic 
pain subjects but not healthy controls.
Of additional interest are the distinct anatomic patterns of the correlations between FAL 
BLBP and pain sensitivity and tolerance between groups. In CON subjects, FAL BLBP was 
mainly associated with pain sensitivity and tolerance in regions whose function is thought to 
be primarily nociceptive, e.g. cingulate, thalamus, insula, and precentral gyrus (Figures 3 
and 4; Online Resources 5, 6, and 7; Apkarian et al. 2005; Tracey 2008). However, in FM 
subjects, FAL BLBP was associated with pain sensitivity and tolerance in regions more 
involved in emotional and stress regulation, e.g. parahippocampal gyrus, temporal pole, and 
hippocampus (Forkmann et al. 2013; Mutso et al. 2012; Olson et al. 2007; Ploghaus et al. 
2001). This spatial discrepancy is consistent with previous studies that have shown that 
individuals with FM exhibit markedly different patterns of brain activation and connectivity 
in response to pain than healthy controls (Gracely et al. 2002; Kim et al. 2015; Loggia et al. 
2014; Jensen et al. 2012). Taken together, the evidence suggests that differential DA function 
in FM patients may contirbute to the perception of chronic pain in this disorder.
We did not detect significant changes in DA transmission during performance of a working 
memory task, whereas a previous study reported DA release in healthy controls during 2-
back performance (Aalto et al. 2005). It is possible that differences in task presentation, 
duration of task, and response requirements could account for the apparent discrepant results 
between the respective samples.
There are several limitations to the current study. The sample size is relatively small 
(although not uncommon for neuroligand PET studies), which introduces the risk of both 
Type I and II errors. We acknowledge that this is a preliminary analysis, and replication in a 
larger cohort will be necessary to substantiate our results. However, our findings are 
generally consistent with previous work, lending credence to our interpretation. Specifically, 
group differences in baseline FAL BP in the ACC are in line with evidence that these regions 
are associated with chronic pain pathologies (Baliki et al. 2006; Luerding et al. 2008). 
Additionally, as mentioned above, significant negative correlations between striatal FAL 
BLBP and experimental pain tolerance was observed both here and in previously published 
work (Martikainen et al. 2005; Martikainen et al. 2015; Scott et al. 2006).
Another potential concern in the current study is that we did not replicate the group 
differences in striatal D2/D3 receptor binding in previous studies of FM (Wood et al. 2007) 
and related chronic pain disorders (Cervenka et al. 2006; Hagelberg et al. 2003a; Hagelberg 
et al. 2003b; Martikainen et al. 2005; Pertovaara et al. 2004; Martikainen et al. 2015). One 
potential explanation for this apparent discrepancy is that the population samples across 
these studies had different pain disorders. As indicated previously, the various pain 
syndromes may not have equivalent neurochemical profiles. Additionally, the previous 
studies excluded for psychiatric disorders, which, while reducing variance within the 
sample, may select for individuals whose pathology is different from the clinical average 
(Clauw 2009). In our study, we did not exclude FM subjects with past or present affective 
disorders (e.g. depression, generalized anxiety disorder). Therefore, our results may be a 
function of a sample that is more phenotypically representative of this chronic pain 
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population. We also acknowledge that the use of different D2/D3 radioligands across studies 
could lead to discrepant results.
There are two additional limitations that warrant mention. First, some of our FM subjects 
were taking medication specifically indicated for FM (e.g., pregabalin). Although there are 
no known associations between these medications and FAL BLBP, we were unable to match 
the control sample for these medications, which could be a potential confound. Second, we 
elected to use an “attentional baseline” scan, which does not allow comparison of the FAL 
WMBP from our N-back challenge with a “true” resting baseline (wherein the subject does 
not perform a task). Instead, we elected to control for motor activation and attentional 
processing with the 0-back task. Although obtaining a third, resting scan would have been 
the ideal study design, the cost of a third FAL scan was prohibitive for this pilot study.
In conclusion, the present work is the first to investigate extrastriatal D2/D3 receptor 
availability in individuals with FM. We provide evidence of: 1) differences in baseline FAL 
BP between FM and CON groups, 2) negative associations between D2/D3 availability and 
spontaneous pain FM subjects, and 3) negative correlations between D2/D3 availability and 
pain sensitivity and tolerance, with anatomical differences in these relationships between 
FM and CON. The results herein demonstrate the utility of [18F]fallypride PET for 
characterization of putative dysfunction in the DA circuitry of fibromyalgia subjects and 
othe chronic pain disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Voxel-wise results from the CON BLBP > FM BLBP full factorial model contrast. Display 
threshold is p < 0.005, k > 10.
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Figure 2. 
Voxel-wise results from the linear regression between baseline VAS pain and baseline FAL 
BP. Display threshold is p < 0.005, k > 10.
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Figure 3. 
Voxel-wise results from the linear regression between FAL BLBP and average algometry 
sensitivity in FM (left) and CON (right) subjects. Display threshold is p < 0.005, k < 10. For 
each group, slice selection was chosen to illustrate results from the largest cluster extent (see 
Online Resource 5).
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Figure 4. 
Voxel-wise results from the linear regression between FAL BLBP and average algometry 
tolerance in FM (left) and CON (right) subjects. Display threshold is p < 0.005, k < 10. For 
each group, slice selection was chosen to illustrate results from the largest cluster extent (see 
Online Resources 6 and 7).
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Table 1
Subject Demographics and Affective Measures
Variable FM (n = 12) CON (n = 11)
Age 28.3 ± 6.2 28.4 ± 7.3
Race 10C; 2AA 10C; 1AA
Handedness 11R; 1L 10R; 1L
Education 14.8 ± 2.4 15.7 ± 2.1
Tobacco smokers 3 2
Presence of Axis I disorder 2 2
Medications
Antidepressantsa 2 2
Pregabalin 2 0
Benzodiazepines (as needed) 1 0
Opiates (as needed) 2 0
Affective inventories
BDI 7.40 ± 4.6* 2.40 ± 3.2
STAI – state 28.9 ± 9.1 26.7 ± 7.0
STAI – trait 32.4 ± 10 28.5 ± 6.7
PANAS – positive 34.6 ± 7.4 36.8 ± 8.5
PANAS – negative 17.4 ± 8.3 14.1 ± 5.8
All variables are presented as average ± s.d. unless otherwise specified. FM: fibromyalgia; CON: control; BDI: Beck Depression Inventory; STAI: 
State-Trait Anxiety Inventory; PANAS: Positive and Negative Affect Scale; C: Caucasian; AA: African American; R: right-handed; L: left-handed
*indicates significant group differences at p < 0.05
aSelective norepinephrine reuptake inhibitors were not permitted on this study
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Table 2
Subjective Pain Metrics
Variable FM (n = 12) CON (n = 11)
BL WM BL WM
MPQ
Sensory (0 – 33) 12.3 ± 5.5* 12.5 ± 6.8** 0.18 ± 0.4 0.18 ± 0.4
Affective (0 – 12) 4.25 ± 2.7* 3.75 ± 2.7** 0.09 ± 0.3 0.09 ± 0.3
Present pain (0 – 100) 44.3 ± 25* 43.4 ± 27** 0.18 ± 0.6 0.09 ± 0.3
FIQ (0 – 100) 51.8 ± 14* 49.7 ± 16** 5.23 ± 12 4.80 ± 12
BPI
Worst pain (0 – 10) 6.83 ± 1.1* 6.54 ± 1.9** 0.36 ± 0.7 0.45 ± 0.8
Least pain (0 – 10) 2.83 ± 1.6* 3.33 ± 2.3** 0.09 ± 0.3 0.18 ± 0.6
Average pain (0 – 10) 5.21 ± 1.6* 5.25 ± 1.9** 0.36 ± 0.9 0.0
Pain interference (0 – 10) 4.68 ± 2.5* 4.94 ± 2.4** 0.35 ± 1.1 0.34 ± 1.0
Algometry (N/cm2)
Average sensitivity 9.28 ± 5.3* 9.05 ± 5.5** 22.2 ± 6.5 22.5 ± 9.0
Average tolerance 17.3 ± 5.8* 16.5 ± 4.4** 39.9 ± 9.4 41.7 ± 11
Average VAS pain (0 – 100) 43.6 ± 24* 42.8 ± 25** 0.88 ± 1.4 0.93 ± 2.0
All variables are presented as average ± s.d. The anchor scores for each pain index are displayed to the right of the variable, if available. FM: 
fibromyalgia; CON: control; BL: baseline day; WM: working memory day; MPQ: McGill Pain Questionnaire; FIQ: Fibromyalgia Impact 
Questionnaire; BPI: Brief Pain Inventory. Note that VAS measures are taken during the PET scans
*indicates significant difference from control subjects during the baseline scan day (p < 0.05)
**indicates significant difference from control subjects during the working memory scan day (p < 0.05)
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